Modern immunotherapy for kidney cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, the introduction of immune checkpoint inhibitors into the clinical practice as a drug therapy for patients with metastatic renal cell carcinoma (mRCC) has significantly improved treatment outcomes, primarily overall survival, and has also identified new challenges for continuing research in this area. Recently, a number of clinical trials have been conducted to study combinations of immuno-oncological drugs, both among themselves and in combination with targeted therapy, which is likely to serve as a basis for creating other standards of treatment in the future. This review demonstrates the results of randomized phase III studies, which allowed to define modern standards in the treatment of mRCC. Also, the own authors’ experience of using the first immune-oncological drug nivoluumab registered for disseminated kidney cancer is presented. This PD-1 inhibitor was used in the framework of the CA209254 expanded access program as a second-line drug therapy for mRCC patients who had progression of the disease after targeted therapy with antiangiogenic drugs.

Full Text

Restricted Access

About the authors

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Аnna I. Semenova

N.N. Petrov National Medical Research Center of Oncology

Email: mirannia@yandex.ru
PhD, Oncologist, Department of Chemotherapy and Innovative Technologies, Senior Reseracher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation

A. P Oganesyan

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. M Anokhina

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. V Novik

N.N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical University

St. Petersburg, Russia

References

  1. Ljungberg B., Bensalah K., Canfield S., et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913-24. Doi: 10.1016/j. eururo.2015.01.005. PMID: 25616710.
  2. Moch H. WHO classification 2016 and first S 3 guidelines on renal cell cancer: What is important for the practice? Pathol. 2016;37(2):127-33.
  3. Zhang L., Yao L., Li X., Jewett M.A., He Z., Zhou L. Natural history of renal cell carcinoma: an immunohistochemical analysis of growth rate in patients with delayed treatment. J Formos Med Assoc. 2016;115:463-69.
  4. Crespigio J., Berbel L.C.L., Dias M.A., Berbel R.F., Pereira S.S., Pignatelli D., Mazzuco T.L. Von HippelLindau disease: a single gene, several hereditary tumors. J Endocrinol Invest. 2018;41:21-31.
  5. Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. PMID: 25220842.
  6. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2017. 250 с.
  7. Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2015;370:2103-11.
  8. Motzer R.J., et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J Clin Oncol. 2015;33:1430-37.
  9. Motzer R.J., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-13.[
  10. Atkins M.B., et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 2017;35 (Suppl., Abstr. 4505).
  11. Choueiri T.K., et al. First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. J Clin Oncol. 2017;35(Suppl. Abstr. 4504).
  12. Chowdhury S., et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2017;35(Suppl., Abstr.4506).
  13. Escudier B., Tannir N.M., McDermott D., et al. CheckMate 214: efficacy and safety of nivolumab. ipilimumab (N.I) v sunitinib (S) for treatmentnaive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Ann Oncol. 2017;28(Suppl. 5).
  14. Schmidinger M. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. Curr Opin Urol. 2018;28(1):29-34. doi: 10.1097/MOU.0000000000000456. PMID: 29045250.
  15. Barata P.C., Rini B. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507-24. doi: 10.3322/caac.21411.
  16. Ross K., Jones R.J. Immune checkpoint inhibitors in renal cell carcinoma. Clin Sci. (Lond) 2017;131(21):2627-42. Doi: 10.1042/ CS20160894. PMID: 29079639.
  17. Beckermann K.E., Johnson D.B., Sosman J.A. PD-1/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol. 2017;13(1):77-84. doi: 10.1080/1744666X.2016.1214575.
  18. Poprach A., Lakomy R., Büchler T. Immunotherapy of renal cell carcinoma. Clin Onkol. 2017;30(Suppl. 3):55-61. doi: 10.14735/amko20 1 73S55. PMID: 29239194.
  19. Adapted from poster presented by E.R. Plimack et al. 15th International Kidney Cancer Symposium. November 4-5, 2016. Miami, FL, USA.
  20. Motzer R.J., Escudier B., McDermott D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-13. doi: 10.1056/NEJMoa1510665. PMID: 26406148.
  21. Powles T., Staehler M., Ljungberg B., et al. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol. 2016;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. PMID: 26508312.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies